去年12月中国CPI、PPI数据将公布；CES2026将开幕丨一周前瞻

Economic Data and Events - China will release December CPI and foreign exchange reserve data in the week of January 5 to January 11, 2026 [1] - The People's Bank of China will have a total of 13,236 billion yuan in reverse repos maturing [1] - The 16th China Internet Industry Annual Conference will be held in Beijing from January 7 to 8, 2026 [1] - The Eurozone will release December CPI and PMI data, while the US will publish the December non-farm payroll report [1] Stock Market Developments - Over 1,600 billion yuan in market value of restricted stocks will be unlocked this week, with 36 stocks involved, totaling over 4.3 billion shares [5][6] - Notable stocks include Baili Tianheng with a market value of 963.19 billion yuan, Guolian Minsheng at 180.08 billion yuan, and Jianshe Industrial at 168.95 billion yuan [6] New Stock Offerings - Two new stocks will be available for subscription: Zhixin Co., Ltd. on January 6 with a subscription limit of 180,000 shares at 21.88 yuan per share, and Kema Materials on the same day with a limit of 9,414,000 shares at 11.66 yuan per share [22][23] Policy and Regulatory Updates - The State Council has issued a comprehensive action plan for solid waste management, aiming for significant improvements by 2030, including a target of 4.5 billion tons of annual comprehensive utilization of solid waste [9] - The plan emphasizes a full-chain management approach across various sectors, including industrial and urban waste [9] Industry Insights - The low-altitude economy in Shanghai is projected to reach a core industry scale of around 80 billion yuan by 2028, with a complete industrial chain for new low-altitude aircraft [11][12] - The commercial aerospace sector is expected to see significant growth, with multiple new rocket launches planned and advancements in reusable rocket technology [13][19] Pharmaceutical Sector Developments - In 2025, China approved 76 innovative drugs, surpassing the previous year's total and achieving a record high, with over 1,300 billion USD in licensing transactions [14][15] - The focus for 2026 will be on next-generation ADCs, dual/multi-antibodies, small nucleic acids, and CAR-T therapies [15][16]